Skip to main content

Table 2 Rates of genotypes of analyzed genes in groups of patients with optimal and non-optimal response to TKI therapy

From: Exome, transcriptome and miRNA analysis don’t reveal any molecular markers of TKI efficacy in primary CML patients

Gene and reference SNP Reference allele Variant allele   Patients with optimal response at 6 months (n = 32) Patients with non-optimal response at 6 months (n = 30) р-value
ANKRD35
rs11579366
G C genotype G/G G/C C/C G/G G/C C/C 0,16
rate, % 9 50 41 29 39 32
DNAH9
rs1990236
G A genotype G/G G/A A/A G/G G/A A/A 0,33
rate, % 72 22 6 57 39 4
MAGEC1
rs176037
C T genotype C/C C/T T/T C/C C/T T/T 0,68
rate, % 53 20 27 41 32 27
TOX3
rs10653661
A ATTTCT genotype A/A A/ ATTTCT ATTTCT/ ATTTCT A/A A/ ATTTCT ATTTCT/ ATTTCT 0,87
rate, % 22 56 22 23 50 27
THSD1
rs3803264
G A genotype G/G G/A A/A G/G G/A A/A 0,38
rate, % 6 44 50 12 27 61
MORN2
rs3099950
G A genotype G/G G/A A/A G/G G/A A/A 0,48
rate, % 69 31 0 77 23 0
PTCRA
rs9471966
G A genotype G/G G/A A/A G/G G/A A/A 0,88
rate, % 56 38 6 50 43 7
  1. SNP single nucleotide polymorphism